2018
DOI: 10.1111/dom.13576
|View full text |Cite
|
Sign up to set email alerts
|

What the diabetes data in the FOURIER trial fail to show

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
7
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 8 publications
0
7
0
Order By: Relevance
“…In the FOURIER and ODYSSEY OUTCOMES trials, the treatment with alirocumab or evolocumab did not worsen glycaemic control in subjects with diabetes at baseline or increase NOD in subjects without diabetes at baseline, when compared to placebo . A recent paper highlighted some discrepancies in diabetes incident cases between different reports of the FOURIER trial and suggested that an increase in relative risk for NOD could have been detected in FOURIER if the initially reported numbers and a longer follow‐up would have been used (3.6 years, as was initially proposed) . However, no studies have so far demonstrated differences in the incidence of NOD in normoglycaemic or pre‐diabetic individuals treated with alirocumab or evolocumab treatment placebo (see Table ) .…”
Section: Safety Of Pcsk9 Inhibitors In T2dm Patientsmentioning
confidence: 99%
See 1 more Smart Citation
“…In the FOURIER and ODYSSEY OUTCOMES trials, the treatment with alirocumab or evolocumab did not worsen glycaemic control in subjects with diabetes at baseline or increase NOD in subjects without diabetes at baseline, when compared to placebo . A recent paper highlighted some discrepancies in diabetes incident cases between different reports of the FOURIER trial and suggested that an increase in relative risk for NOD could have been detected in FOURIER if the initially reported numbers and a longer follow‐up would have been used (3.6 years, as was initially proposed) . However, no studies have so far demonstrated differences in the incidence of NOD in normoglycaemic or pre‐diabetic individuals treated with alirocumab or evolocumab treatment placebo (see Table ) .…”
Section: Safety Of Pcsk9 Inhibitors In T2dm Patientsmentioning
confidence: 99%
“…15,61 A recent paper highlighted some discrepancies in diabetes incident cases between different reports of the FOURIER trial and suggested that an increase in relative risk for NOD could have been detected in FOURIER if the initially reported numbers and a longer follow-up would have been used (3.6 years, as was initially proposed). 91 However, no studies have so far demonstrated differences in the incidence of NOD in normoglycaemic or pre-diabetic individuals treated with alirocumab or evolocumab treatment placebo (see Table 2). 15,60,61,92,93 In a pooled analysis of 10 ODYSSEY trials, the impact of alirocumab on NOD and pre-diabetes incidence in subjects without diabetes was assessed over a period of 24-104 weeks (n = 4974).…”
Section: Odyssey-combo IImentioning
confidence: 99%
“…Much discussion has developed over the multiple publications from the FOURIER trial. The major discussion centres around the reported diabetes prevalence and incidence as seen in the paper by van Burggen and Luijendijk . The FOURIER authors report in different publications the prevalence and incidence of diabetes, which varies from 33.9% to ~40%.…”
Section: Pcsk9 Fourier Trialmentioning
confidence: 99%
“…The major discussion centres around the reported diabetes prevalence and incidence as seen in the paper by van Burggen and Luijendijk. 18 The FOURIER authors report in different publications the prevalence and incidence of diabetes, which varies from 33.9% to~40%. It is unclear from FOURIER trial publications which is the correct number for the prevalence and incidence of diabetes in the trial.…”
mentioning
confidence: 99%
“…Drs Van Bruggen and Luijendijk note they were confused by what they thought were differences in the prevalence and incidence of diabetes in different papers from FOURIER . The first paper they cite was the design paper which was published while the trial was ongoing .…”
mentioning
confidence: 99%